Skip to main content
Premium Trial:

Request an Annual Quote

US Navy Awards Xeotron $3M to Build New Oligo Technology

NEW YORK, Feb. 4 - Xeotron has won a $3 million US Navy contract to develop a new system that can assemble long DNA sequences, the company said on Monday.

 

The system will be designed to produce multi-strands of oligonucleotides. Xeotron hopes that the new system would be able to shorten the process of oligo synthesis to less than 12 hours, which could make it possible to synthesize large DNA segments in roughly 24 hours.

 

As designed, the system would not require photomask lithography or robotics, the company said.

 

Xeotron's technology platform combines photochemistry, digital photonics, and microfluidics. The company uses a method of in situ photosynthesis coupled with digital light and photosensitive chemistry in a microfluidic chip to produce large amounts of DNA or peptides.

 

Xeotron, a Houston-based startup, currently markets chips for cancer-gene expression, HIV genotyping, human gene expression profiling, and drug discovery.

 

The project is funded by the Defense Advanced Research Projects Agency through the Navy's Office of Special Technology.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.